The US FDA approved 23 new drugs in the first 6 months of 2017 (TABLE 1). This is more than the agency approved in the entirety of 2016, Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 16 | AUGUST 2017 | 519…
Drug pipeline 2Q17
FDA approvals continue the upward trend noted in the first quarter, with the registration of the first deuterated compound, a new small- molecule drug for amyotrophic lateral sclerosis (ALS) and acceler- ated approval of Imfinzi, a checkpoint inhibitor for use in bladder cancer. A slew of drugs gained breakthrough therapy designation (Supplementary Table 1). The first approved gene therapy Glybera was axed for economic reasons; two biosimilars ran into trouble at the FDA. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 8 AUGUST 2017 Click here to…